Revolade

Eltrombopag (Revolade) instruction manual

Common name: Eltrombopag

Trade name: Revolade

All names: Eltrombopag, Eltrombopag, Revolade, Elbonix

1. Eltrombopag indications

Eltrombopag tablets Revolade is a thrombopoietin receptor agonist suitable for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura and patients who have poor response to corticosteroids, immunoglobulins or splenectomy.

Revolade should only be used in patients with ITP whose thrombocytopenia and clinical conditions increase the risk of bleeding. Revolade should not be used with the intention of normalizing normal platelet counts. Eltrombopag shows promise in treating aplastic anemia.

Eltrombopag can also be used to treat thrombocytopenia in patients with chronic hepatitis C.

2. Eltrombopag usage and dosage

The starting dose of Eltrombopag is 50 mg once a day; for Oriental patients or patients with moderate or severe hepatic insufficiency, the starting dose is 25 mg once a day, administered on an empty stomach (1 hour or 2 hours before meals).

Allow 4 hours between administration of eltrombopag and other medications, foods, or polyvalent cation (e.g., iron, calcium, aluminum, magnesium, selenium, and zinc) additives. To reduce the risk of bleeding, adjust the daily dose to achieve and maintain a platelet count ≥50 X 109/L. Do not exceed 75 mg daily dose.

Take it for two weeks, and increase the dosage to the maximum dose of 150mg per day in two-week cycles. The primary endpoint was hematological response, with an initial assessment after 12 weeks. Stop treatment if no hematological response is observed after 16 weeks.

3. Adverse reactions of eltrombopag

The most common adverse reactions are: nausea, vomiting, menorrhagia, myalgia, paresthesias, cataracts, dyspepsia, ecchymosis, thrombocytopenia, increased ALT/AST and conjunctival hemorrhage.

4. Eltrombopag contraindications

None.

5. Pregnant women using Eltrombopag

Pregnancy: It may cause fetal harm.

Nursing mothers: Eltrombopag should be discontinued.

6. Eltrombopag for children

There is no clinically effective basis for using this product in children.

7. Eltrombopag drug interactions

Eltrombopag is an inhibitor of the OATP1B1 transporter. Monitor patients closely for signs and symptoms of excessive drug exposure to OATP1B1 substrates (e.g., rosuvastatin) and consider a dose reduction of these drugs.

Polyvalent cations (e.g., iron, calcium, aluminum, magnesium, selenium, and zinc) significantly reduce the absorption of eltrombopag; eltrombopag must not be taken within 4 hours of any medicine containing polyvalent cations such as antacids, dairy products, and mineral supplements.

8. Storage of Eltrombopag

Store at room temperature and away from light.